You are here: Industry Insights > Market News > Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

SG-DJ10 Capsule and Tablet Sample Checkweigher

NADP+

NMN

Ceritinib (LDK378) CAS:1032900-25-6

SG-JN10 0.1mg Tablet Capsule Check Weigher

β-Nicotinamide Adenine Dinucleotide (NAD+)

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

firstwordpharmaAugust 04, 2021

Tag: Sinovac , COVID-19 , Vaccine

Favorites

Chilean health authorities said on Tuesday that Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic infection among millions of Chileans who received it between February and July, as reported This is Money

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

Coronavac was 86% effective in preventing hospitalisation, 89.7% effective in preventing intensive care unit admission and 86% effective in preventing deaths within the population, said health official Rafael Araos.

Previous:Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Next:Rupture Disc Market in Industrial Machinery Industry | COVID-19 Impact & Recovery Analysis | Technavio

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study | Pharmasources.com

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.

You may like
More>>

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Hualan-Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

2024-2025 quadrivalent/trivalent flu vaccine

Hualan good immunogenicity performance Influenza Vaccine

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Quadrivalent Influenza Vaccine in 2022

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

Related News

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

You may likeMore>>

You may like
More>>